Tenaya Therapeutics, a clinical-stage biotechnology firm based in South San Francisco, has announced significant new clinical data for its gene therapy product, TN-201. This information will be presented during the American Heart Association (AHA) 2025 Scientific Sessions, scheduled for November 7-10, 2025, in New Orleans, Louisiana. The findings are expected to provide insights into the safety and efficacy of TN-201 for treating patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM).
Key Presentations Highlighting Interim Results
The AHA presentation will focus on interim safety and efficacy results from the first two dose cohorts of the MyPEAK-1 Phase 1b/2a clinical trial. This trial evaluates TN-201, which aims to address HCM caused by insufficient levels of myosin-binding protein C (MyBP-C). The results will be presented by Milind Y Desai, M.D., MBA, director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic, on November 8, 2025, from 10:25 am to 10:35 am CT.
The presentation is titled “TN-201, an Investigational MYBPC3 Gene Replacement Therapy: Interim Clinical Data from MyPEAK-1.” This session is part of the Late-Breaking Science segment, indicating its significance to ongoing research in the field.
Preclinical Insights into Ischemic Heart Failure Treatment
In addition to the MyPEAK-1 data, Tenaya will present results from a preclinical study demonstrating the effects of its cellular reprogramming gene therapy in a pig model of ischemic heart failure. This innovative approach aims to enhance cardiac function following ischemic injury through the regeneration of heart cells. The presentation, led by Kathy Ivey, Senior Vice President of Research at Tenaya, will take place on November 9, 2025, from 8:00 am to 8:10 am CT.
The title for this presentation is “First Demonstration of Significant and Durable Improvement of Cardiac Function in Pig Model of Ischemic Heart Failure with Direct Reprogramming Delivered Precisely to Infarct Border via Guided Intramyocardial Injection Catheter.” This underlines Tenaya’s commitment to advancing therapies for heart conditions.
Both presentations are expected to provide pivotal data that could influence future treatment protocols for heart disease. Copies of the presentations will be accessible in the “Our Science” and “Investors” sections of Tenaya’s website following each session.
Upcoming Conference Call for Investors
Tenaya management will host a conference call on November 10, 2025, at 8:00 a.m. ET to discuss the findings from the AHA Scientific Sessions. Investors and analysts are encouraged to participate via a webcast, which will be accessible on the investor section of the Tenaya website.
Founded with a mission to develop potentially curative therapies for heart disease, Tenaya Therapeutics is actively working on a pipeline that includes not only TN-201 but also TN-401, aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The company employs advanced techniques in gene therapy and cell regeneration, with ongoing projects targeting various heart-related conditions.
For further details about Tenaya’s initiatives and upcoming events, visit their official website at www.tenayatherapeutics.com.
